Salarius Pharmaceuticals, Inc. filed a report about a merger with Decoy Therapeutics, set to take effect on August 22, 2025, where Salarius stockholders will retain about 7.6% and Decoy stockholders will own 92.4%. The merger is contingent upon achieving at least $6.0 million in qualified financing and the continued listing of Salarius on Nasdaq.